ESR1 and breast carcinoma: The MammaPrint (70-gene signature, Agendia Precision Oncology, Amsterdam, The Netherlands) has been approved by the United States Food and Drug Administration (FDA) to calculate RS for both ER+ and ER- breast cancer patients.